|
Mechanism5-HT2A receptor agonists [+1] |
|
|
|
|
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingPhase 2IIT Long-Term Safety and Persistence of Effectiveness of Manualized MDMA Assisted Therapy for the Treatment of Posttraumatic Stress Disorder - Long-term follow-up of MDMA-assisted therapy for PTSD
An Open-Label, Phase 2, Multicenter Feasibility Study of Manualized MDMA-Assisted Psychotherapy With an Optional fMRI Sub-Study Assessing Changes in Brain Activity in Subjects With Posttraumatic Stress Disorder
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people diagnosed with at least severe PTSD.
The main question it aims to answer is: Do two open-label sessions of MDMA-assisted therapy reduce PTSD symptoms?
Participants will receive three non-drug preparatory sessions followed by two sessions of MDMA-assisted therapy. Each MDMA-assisted therapy session is followed by three non-drug integrative therapy sessions.
100 Clinical Results associated with MAPS Europe B.V.
0 Patents (Medical) associated with MAPS Europe B.V.
100 Deals associated with MAPS Europe B.V.
100 Translational Medicine associated with MAPS Europe B.V.